No misrepresentation of vital status follow-up in PLATO: predefined analyses guarantee the integrity of the benefits of ticagrelor over clopidogrel in the PLATO trial: commentary on: DiNicolantonio JJ, Tomek A, Misrepresentation of vital status follow-up: Challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel, International Journal of Cardiology, 2013 Serebruany VL. Discrepancies in the primary PLATO trial publication and the FDA reviews, International Journal of Cardiology, 2014

Bibliographic Details

Main Authors:	Wallentin, Lars (Author) , Becker, Richard C. (Author) , Cannon, Christopher P. (Author) , Held, Claes (Author) , Himmelmann, Anders (Author) , Husted, Steen (Author) , James, Stefan K. (Author) , Katus, Hugo (Author) , Mahaffey, Kenneth M. (Author) , Pieper, Karen S. (Author) , Storey, Robert F. (Author) , Steg, Philippe Gabriel (Author) , Harrington, Robert A. (Author)
Format:	Article (Journal)
Language:	English
Published:	27 June 2014
In:	International journal of cardiology Year: 2014, Volume: 176, Issue: 1, Pages: 300-302
ISSN:	1874-1754
DOI:	10.1016/j.ijcard.2014.06.029
Online Access:	Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.ijcard.2014.06.029 Verlag, lizenzpflichtig, Volltext: http://www.sciencedirect.com/science/article/pii/S0167527314010961
Author Notes:	Lars Wallentin, Richard C. Becker, Christopher P. Cannon, Claes Held, Anders Himmelmann, Steen Husted, Stefan K. James, Hugo A. Katus, Kenneth M. Mahaffey, Karen S. Pieper, Robert F. Storey, Philippe Gabriel Steg, Robert A. Harrington, on behalf of the PLATO investigators